1. Home
  2. Programs
  3. CME/CE
advertisement

Breaking Silos With STAMP! Detecting Cardiorenal Risk and Integrating Nonsteroidal MRA Therapy in Patients With HF and CKD

30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
  • Overview

    Managing patients with overlapping heart failure (HF) and chronic kidney disease (CKD) requires earlier risk identification, evidence-based treatment, and coordinated care. Join Drs. Javier Morales, Nikolaus Marx, and Brendon Neuen as they explore the STAMP approach, emerging cardiorenal treatment evidence, and practical strategies to optimize therapy and monitoring. Discover how multidisciplinary collaboration can help close gaps in care and improve patient outcomes.

  • Commercial Support

    This activity is supported by an independent educational grant from Bayer AG. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative requires all faculty and planners to disclose financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated to ensure that the content is free from commercial bias.

    The following faculty and planners have disclosed relevant financial relationships with ineligible companies in the past 24 months.

    Faculty: 
    Brendon Neuen, MBBS, PhD
    Associate Professor of Medicine, Director of Kidney Trials
    Royal North Shore Hospital & George Institute for Global Health
    University of New South Wales
    Sydney, Australia

    Research: AstraZeneca, Bayer, Menarini
    Consulting Fees: Alexion, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, CSL Seqirus, Novo Nordisk, Otsuka, Travere Therapeutics

    Nikolaus Marx, MD, FESC, FAHA
    Professor of Medicine / Cardiology
    Head, Department of Internal Medicine I
    University Hospital Aachen
    Aachen, Germany

    Consulting Fees: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, F. Hoffmann-La Roche, Lilly, Novo Nordisk, Sanofi

    Javier Morales, MD, FACP, FACE
    Associate Clinical Professor of Medicine
    Donald and Barbara Zucker School of Medicine at Hofstra Northwell
    Vice President, Advanced Internal Medicine Group, P.C.
    East Hills, NY, USA

    Consulting Fees: Amgen, Bayer, Boehringer Ingelheim, Lilly, Novo Nordisk

    Reviewers/Planners/Authors: 

    • Cindy Davidson has no relevant relationships to disclose. 
    • Elizabeth Lurwick has no relevant relationships to disclose. 
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 
  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • Apply eGFR, UACR, and cardiovascular assessment to identify and stratify overlapping heart failure (HF) and chronic kidney disease (CKD) risk earlier
    • Develop coordinated, multidisciplinary treatment and monitoring plans that integrate foundational HF therapy, kidney protection, and cardiometabolic risk management in patients with CKD and HF
  • Target Audience

    This activity has been designed to meet the educational needs of endocrinologists and primary care physicians as well as all other healthcare professionals involved in managing patients with heart failure (HF) and chronic kidney disease (CKD). 

  • Accreditation and Credit Designation Statements

    This activity has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®).

    EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

    Through an agreement between the Royal College of Physicians and Surgeons of Canada and the European Board for Accreditation of Continuing Education for Health Professionals, Royal College MOC Section 1 credits are deemed to be substantively equivalent to EBAC CPD credits.

    This activity has been designed for a maximum of 0.50 EBAC® CE credit(s)/point(s).Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

  • Provider(s)/Educational Partner(s)


    Global Learning Collaborative (GLC) designs and executes continuing education rooted in evidence-based medicine, clinical need, knowledge gap analysis, and careful consideration of learner feedback. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology is founded on a commitment to continuing medical education and the innovative assessment of its effects on clinical practice. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
  • Overview

    Managing patients with overlapping heart failure (HF) and chronic kidney disease (CKD) requires earlier risk identification, evidence-based treatment, and coordinated care. Join Drs. Javier Morales, Nikolaus Marx, and Brendon Neuen as they explore the STAMP approach, emerging cardiorenal treatment evidence, and practical strategies to optimize therapy and monitoring. Discover how multidisciplinary collaboration can help close gaps in care and improve patient outcomes.

  • Commercial Support

    This activity is supported by an independent educational grant from Bayer AG. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative requires all faculty and planners to disclose financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated to ensure that the content is free from commercial bias.

    The following faculty and planners have disclosed relevant financial relationships with ineligible companies in the past 24 months.

    Faculty: 
    Brendon Neuen, MBBS, PhD
    Associate Professor of Medicine, Director of Kidney Trials
    Royal North Shore Hospital & George Institute for Global Health
    University of New South Wales
    Sydney, Australia

    Research: AstraZeneca, Bayer, Menarini
    Consulting Fees: Alexion, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, CSL Seqirus, Novo Nordisk, Otsuka, Travere Therapeutics

    Nikolaus Marx, MD, FESC, FAHA
    Professor of Medicine / Cardiology
    Head, Department of Internal Medicine I
    University Hospital Aachen
    Aachen, Germany

    Consulting Fees: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, F. Hoffmann-La Roche, Lilly, Novo Nordisk, Sanofi

    Javier Morales, MD, FACP, FACE
    Associate Clinical Professor of Medicine
    Donald and Barbara Zucker School of Medicine at Hofstra Northwell
    Vice President, Advanced Internal Medicine Group, P.C.
    East Hills, NY, USA

    Consulting Fees: Amgen, Bayer, Boehringer Ingelheim, Lilly, Novo Nordisk

    Reviewers/Planners/Authors: 

    • Cindy Davidson has no relevant relationships to disclose. 
    • Elizabeth Lurwick has no relevant relationships to disclose. 
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 
  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • Apply eGFR, UACR, and cardiovascular assessment to identify and stratify overlapping heart failure (HF) and chronic kidney disease (CKD) risk earlier
    • Develop coordinated, multidisciplinary treatment and monitoring plans that integrate foundational HF therapy, kidney protection, and cardiometabolic risk management in patients with CKD and HF
  • Target Audience

    This activity has been designed to meet the educational needs of endocrinologists and primary care physicians as well as all other healthcare professionals involved in managing patients with heart failure (HF) and chronic kidney disease (CKD). 

  • Accreditation and Credit Designation Statements

    This activity has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®).

    EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

    Through an agreement between the Royal College of Physicians and Surgeons of Canada and the European Board for Accreditation of Continuing Education for Health Professionals, Royal College MOC Section 1 credits are deemed to be substantively equivalent to EBAC CPD credits.

    This activity has been designed for a maximum of 0.50 EBAC® CE credit(s)/point(s).Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

  • Provider(s)/Educational Partner(s)


    Global Learning Collaborative (GLC) designs and executes continuing education rooted in evidence-based medicine, clinical need, knowledge gap analysis, and careful consideration of learner feedback. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology is founded on a commitment to continuing medical education and the innovative assessment of its effects on clinical practice. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free